Comparative Pharmacology
Head-to-head clinical analysis: AIRDUO DIGIHALER versus PULMICORT RESPULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIRDUO DIGIHALER versus PULMICORT RESPULES.
AIRDUO DIGIHALER vs PULMICORT RESPULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by increasing cyclic AMP. Fluticasone propionate is a corticosteroid with anti-inflammatory activity that inhibits inflammatory mediators and cells.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Two inhalations (umeclidinium 62.5 mcg and vilanterol 25 mcg per inhalation) orally once daily.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
None Documented
None Documented
Fluticasone furoate: terminal elimination half-life is approximately 24 hours. Vilanterol: terminal elimination half-life is approximately 11 hours. The long half-life of fluticasone furoate supports once-daily dosing, while vilanterol's half-life allows for sustained bronchodilation over 24 hours.
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Fluticasone furoate and vilanterol are primarily eliminated via biliary/fecal routes. For fluticasone furoate, approximately 90% of an oral dose is excreted in feces as parent drug and metabolites, with <1% in urine. Vilanterol is predominantly excreted via feces (∼70%) as metabolites, with ∼20% in urine.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Category C
Category C
Inhaled Corticosteroid/LABA Combination
Inhaled Corticosteroid